Palisade Bio Inc (PALI) Actualités

Form 3 - Initial statement of beneficial ownership of securities

Palisade Bio Reports First Quarter 2024 Financial Results and Provides Business Update

– Company on track to commence Phase 1 human clinical study of lead product candidate, PALI-2108, for the...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Form D - Notice of Exempt Offering of Securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form S-3 - Registration statement under Securities Act of 1933

Palisade Bio Appoints Margery Fischbein to its Board of Directors

Wall Street and biotech industry veteran with expertise across corporate finance, business development...

Palisade Bio Announces Closing of $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 07, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical...

Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules

Carlsbad, CA, May 02, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical...

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis...

Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach

– Collaboration grants Palisade Bio access to cutting-edge expertise and tools in bioinformatics – Partnership...

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Company continues advancing ongoing development of targeted therapies for ulcerative colitis (UC...